Related Experiment Video

Updated: Aug 16, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Angiogenesis inhibitors in the treatment of cancer

Jay Rhee1, Paulo M Hoff

  • 1University of Texas MD Anderson Cancer Center, Department of GI Medical Oncology, 1515 Holcombe Boulevard, Unit 426 Houston, TX 77030, USA.

Expert Opinion on Pharmacotherapy
|August 10, 2005
PubMed

Insights

Antiangiogenesis therapy, targeting tumor blood vessel growth, is a key cancer research area. Bevacizumab (Avastin), an anti-VEGF antibody, is a significant advancement for colorectal cancer treatment.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Cancer research increasingly focuses on non-conventional antitumor agents.
  • Antiangiogenesis therapy, targeting tumor vascularization, has emerged as a major therapeutic strategy.
  • The development of anti-vascular endothelial growth factor (VEGF) agents represents a significant advancement.

Purpose of the Study:

  • To review the background of antiangiogenesis research.
  • To discuss preclinical and clinical data on bevacizumab for colorectal cancer.
  • To explore the potential of antiangiogenesis agents in various malignancies.

Main Methods:

  • Review of published clinical trials and preclinical data.
  • Analysis of FDA approval of bevacizumab (Avastin).
  • Examination of ongoing research in multiple tumor types.

Main Results:

  • Bevacizumab (Avastin) gained FDA approval in 2004 for colorectal cancer, marking a milestone.
  • Antiangiogenesis agents are under investigation for renal cell carcinoma, lung cancer, breast cancer, and more.
  • Ongoing research continues to explore VEGF and other angiogenesis mediators.

Conclusions:

  • Antiangiogenesis therapy, particularly with bevacizumab, shows significant promise in cancer treatment.
  • Targeting tumor angiogenesis is a rapidly evolving field with broad applicability.
  • Further research is essential to optimize the utility of these agents across various cancers.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...